Engineered FK506-binding protein 12 domain (Engineered FKBP12)

The engineered FKBP12 domain (often called a "destabilizing domain") is a modified version of the human FK506-binding protein 12 (FKBP12), typically incorporating one or more site-specific mutations (such as F36V, L106P, or additional surface residue changes) to create a fusion protein that is unstable and rapidly degraded in cells unless stabilized by a small synthetic ligand, such as Shield-1. In contrast to the native FKBP12’s function as a peptidyl-prolyl cis-trans isomerase and immunophilin that binds drugs like FK506 and rapamycin, the engineered domains are not used to target endogenous pathways, but rather as a tool to allow ligand-dependent, reversible control of the protein levels of any chosen fusion partner in cellular, animal, or other experimental systems. This makes the engineered FKBP12 domain a powerful resource for studying acute protein function and for temporal control of protein activity in research settings[3][5]. The target is not considered a classical therapeutic target (receptor, enzyme, transporter, etc.), but rather a research tool that enables conditional protein stabilization in biological systems[3][5]. There is no disease linkage nor established role in human pathophysiology. The most widely used ligand for engineered FKBP12 domains is Shield-1; specificity can be further improved depending on the selected amino acid substitutions in the FKBP12 sequence[3][5]. This entry is considered "incorrect" as a therapeutic target because “engineered FKBP12 domain” does not refer to a natural biological molecule but to an artificial construct used specifically for research applications, not for modulating endogenous disease pathways.

Other names

Engineered FKBPFKBP12 destabilizing domainFKBP12 DDligand-dependent destabilizing domain (with mutation, e.g., FKBP12 F36V, FKBP12 L106P, FKBP12 F36V/L106P)

Small-molecule-induced stabilization of engineered domains fused to a target protein, thereby controlling target protein levels in living cells. Destabilization in the absence of ligand, rapid proteasomal degradation of the tagged protein. No direct modulation of endogenous pathways or receptors (unlike wild-type FKBP12).